The current state of paclitaxel and radiation in the combined-Modality therapy of non-small cell lung cancer

Hak Choy, Rob MacRae

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The results of randomized trials have prompted an evolution in the treatment approach to inoperable locally advanced non-small cell lung cancer, from radio-therapy alone to sequential chemoradiotherapy and now to concurrent chemoradiotherapy. The improvement in outcome seen with a concurrent chemoradiotherapy approach may be because of spatial cooperation, enhanced radiosensitization, and/or enhanced cytotoxicity. The taxanes, specifically paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), delivered in combination with radiation have been extensively examined in both preclinical and clinical studies. Several mechanisms have been suggested to explain the enhanced tumor cell kill seen with paclitaxel and radiation, and phase II studies have examined this combination in the setting of inoperable stage III non-small cell lung cancer. This review will explore some of the studies with this treatment approach in locally advanced disease. We also will briefly discuss some of the ongoing trials that are attempting to refine the delivery of concurrent thoracic radiation and paclitaxel-based chemotherapy.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalSeminars in Oncology
Volume28
Issue number4 SUPPL. 14
StatePublished - 2001

Fingerprint

Combined Modality Therapy
Paclitaxel
Non-Small Cell Lung Carcinoma
Chemoradiotherapy
Radiation
Taxoids
Radio
Thorax
Therapeutics
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

The current state of paclitaxel and radiation in the combined-Modality therapy of non-small cell lung cancer. / Choy, Hak; MacRae, Rob.

In: Seminars in Oncology, Vol. 28, No. 4 SUPPL. 14, 2001, p. 17-22.

Research output: Contribution to journalArticle

@article{6baf04fc9bd64bce992c3e8edc2b7a00,
title = "The current state of paclitaxel and radiation in the combined-Modality therapy of non-small cell lung cancer",
abstract = "The results of randomized trials have prompted an evolution in the treatment approach to inoperable locally advanced non-small cell lung cancer, from radio-therapy alone to sequential chemoradiotherapy and now to concurrent chemoradiotherapy. The improvement in outcome seen with a concurrent chemoradiotherapy approach may be because of spatial cooperation, enhanced radiosensitization, and/or enhanced cytotoxicity. The taxanes, specifically paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), delivered in combination with radiation have been extensively examined in both preclinical and clinical studies. Several mechanisms have been suggested to explain the enhanced tumor cell kill seen with paclitaxel and radiation, and phase II studies have examined this combination in the setting of inoperable stage III non-small cell lung cancer. This review will explore some of the studies with this treatment approach in locally advanced disease. We also will briefly discuss some of the ongoing trials that are attempting to refine the delivery of concurrent thoracic radiation and paclitaxel-based chemotherapy.",
author = "Hak Choy and Rob MacRae",
year = "2001",
language = "English (US)",
volume = "28",
pages = "17--22",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 14",

}

TY - JOUR

T1 - The current state of paclitaxel and radiation in the combined-Modality therapy of non-small cell lung cancer

AU - Choy, Hak

AU - MacRae, Rob

PY - 2001

Y1 - 2001

N2 - The results of randomized trials have prompted an evolution in the treatment approach to inoperable locally advanced non-small cell lung cancer, from radio-therapy alone to sequential chemoradiotherapy and now to concurrent chemoradiotherapy. The improvement in outcome seen with a concurrent chemoradiotherapy approach may be because of spatial cooperation, enhanced radiosensitization, and/or enhanced cytotoxicity. The taxanes, specifically paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), delivered in combination with radiation have been extensively examined in both preclinical and clinical studies. Several mechanisms have been suggested to explain the enhanced tumor cell kill seen with paclitaxel and radiation, and phase II studies have examined this combination in the setting of inoperable stage III non-small cell lung cancer. This review will explore some of the studies with this treatment approach in locally advanced disease. We also will briefly discuss some of the ongoing trials that are attempting to refine the delivery of concurrent thoracic radiation and paclitaxel-based chemotherapy.

AB - The results of randomized trials have prompted an evolution in the treatment approach to inoperable locally advanced non-small cell lung cancer, from radio-therapy alone to sequential chemoradiotherapy and now to concurrent chemoradiotherapy. The improvement in outcome seen with a concurrent chemoradiotherapy approach may be because of spatial cooperation, enhanced radiosensitization, and/or enhanced cytotoxicity. The taxanes, specifically paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), delivered in combination with radiation have been extensively examined in both preclinical and clinical studies. Several mechanisms have been suggested to explain the enhanced tumor cell kill seen with paclitaxel and radiation, and phase II studies have examined this combination in the setting of inoperable stage III non-small cell lung cancer. This review will explore some of the studies with this treatment approach in locally advanced disease. We also will briefly discuss some of the ongoing trials that are attempting to refine the delivery of concurrent thoracic radiation and paclitaxel-based chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0034796675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034796675&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 17

EP - 22

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 14

ER -